NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

Alpha-1抗胰蛋白酶缺乏症(AATD)- 市場分析,流行病學,市場預測

Alpha Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 453798
出版日期 按訂單生產 內容資訊 英文 200 Pages
商品交期: 10個工作天內
價格
Alpha-1抗胰蛋白酶缺乏症(AATD)- 市場分析,流行病學,市場預測 Alpha Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast-2030
出版日期: 按訂單生產內容資訊: 英文 200 Pages
簡介

Alpha-1抗胰蛋白酶缺乏症(AATD),是由於在體內未生成充足的AAT蛋白質,內臟器官暴露在嗜中性白血球彈性蛋白酶等蛋白質分解酵素有害的作用而發病。肝臟產生的AAT蛋白質,保護肺等內臟器官免受蛋白質分解酵素的侵害發揮了重要作用,不過,根據不同原因蛋白質會進入血液中而無法按預期運作,提高肺部疾病的風險。

根據DelveInsight,美國及EU5個國家(德國、西班牙、義大利、法國、英國)的Alpha-1抗胰蛋白酶缺乏症(AATD)的患病人數2017年是17萬5,009人。這個6個國家的市場規模,2017年是6億9,800萬美元,不過,預計至2030年期間更加增加。

本報告提供美國及EU5個國家(德國,西班牙,義大利,法國,英國)的Alpha-1抗胰蛋白酶缺乏症(AATD)市場趨勢,流行病學的歷史與預測,疾病詳細的分析。還有Alpha-1抗胰蛋白酶缺乏症(AATD)的治療方法,新的治療藥,各種治療方法的市場佔有率,目前市場規模與預測,目前治療方法/演算法,市場推動要素,市場障礙,未滿足需求等資訊也。

目錄

第1章 主要洞察

第2章 Alpha-1抗胰蛋白酶缺乏症概要

第3章 Alpha-1抗胰蛋白酶缺乏症的SWOT分析

第4章 Alpha-1抗胰蛋白酶缺乏症的患者佔有率

第5章 Alpha-1抗胰蛋白酶缺乏症市場概要

第6章 疾病的背景和概要

  • 簡介
  • 症狀
  • 病因
  • 危險因素
  • AATD的遺傳的遺傳
  • 臨床症狀
  • 病理生理學
  • 生物標記
  • 診斷
  • 診斷的延遲

第7章 流行病學和患者人口

  • 主要調查結果
  • 主要6個國家的Alpha1anti胰蛋白酶缺乏症患者數

第8章 各國Alpha1anti胰蛋白酶缺乏症的流行病學

  • 假設和根據
  • 美國
    • AATD的發病數
    • AATD和確診的患者數
    • AATD診斷患者的遺傳基因型
    • AATD相關合併症
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國

第9章 治療

  • 目前治療方法
    • 增強療法
    • 基因治療
    • 生活方式的變化
    • 新的治療方法

第10章 治療流程

  • 肺部疾病伴隨的Alpha-1抗胰蛋白酶缺乏症的管理
  • 肝疾病伴隨的Alpha-1抗胰蛋白酶缺乏症的管理

第11章 未滿足需求

第12章 Alpha-1抗胰蛋白酶缺乏症的治療貢獻的組織

第13章 案例報告

第14章 已上市醫藥品

  • Prolastin C: Grifols
  • Glassia: Kamada
  • Aralast: Shire
  • Zemaira:CSL Behring
  • Alfalastin: LFB Biotechnologies
  • Trypsone: Grifols

第15章 新治療方法

  • Inhaled AAT (Glassia IH): Kamada Ltd
  • ALN-AAT02: Alnylam Pharmaceuticals
  • ARO-AAT: Arrow Head Pharmaceuticals
  • VX-814: Vertex Pharmaceuticals
  • Alvelestat (MPH-966): Mereo Biopharma
  • DCR-A1AT: Dicerna Pharmaceuticals

第16章 其他有潛力候選人

  • INBRX-101:Inhibrx
  • Carbamazepine: Novartis Pharmaceuticals
  • VX-864:Vertex Pharmaceuticals

第17章 Alpha-1抗胰蛋白酶缺乏症:主要6市場分析

  • AATD的總合市場規模

第18章 Alpha-1抗胰蛋白酶缺乏症:各國市場分析

  • 美國
    • AATD的總合市場規模
    • 美國的各治療法Alpha-1抗胰蛋白酶缺乏症的市場規模
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國

第19章 對Alpha-1抗胰蛋白酶缺乏症的Grifols的配合措施

第20章 對Alpha1anti胰蛋白酶缺乏症(AATD)患者的美國FDA的配合措施

第21章 市場推動因素

第22章 市場障礙

第23章 Alpha-1抗胰蛋白酶缺乏症的獲取與償付概要

第24章 附錄

章25:DelveInsight的服務內容

第26章 免責聲明

第27章:關於DelveInsight

目錄
Product Code: DIMI0001

DelveInsight's 'Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AATD's in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Alpha Antitrypsin Deficiency (AATD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2017-2030

Alpha Antitrypsin Deficiency (AATD) - Disease Understanding and Treatment Algorithm

Alpha Antitrypsin Deficiency (AATD) occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. AAT protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.

The DelveInsight Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.

Alpha Antitrypsin Deficiency Epidemiology

The Alpha Antitrypsin Deficiency (AATD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency (AATD) in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2030.

According to DelveInsight, the total number of prevalent cases of Alpha Antitrypsin Deficiency (AATD) in 6 MM was found to be 175,009, in the year 2017. 

Alpha Antitrypsin Deficiency Drug Chapters

This segment of the Alpha Antitrypsin Deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current treatment for AATD includes both medicinal and surgical therapies. Both of these categories rely on providing symptomatic relief to the subjects based on the level and severity of their conditions. Commonly used therapy for AATD is similar to chronic obstructive pulmonary disease (COPD) and emphysema treatment: abstinence from smoking, long-acting bronchodilators, antibiotics, inhalations of corticosteroids, and long-acting beta-agonists are recommended. However, the application of such solutions does not increase the functional AAT level in serum. The only currently approved and dedicated treatment for AATD is Augmentation therapy. Weekly intravenous supplementation with the AAT protein purified from pooled healthy donors' plasma that has become available since the end of the 1980s. It is based on the administration of the purified human AAT at a dose of 60  mg/kg per week in order to achieve the protective level of AAT in serum.

Alpha Antitrypsin Deficiency Market Outlook

The Alpha Antitrypsin Deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 6MM, the United States accounts for the largest market size of AATD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain).

Alpha Antitrypsin Deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alpha Antitrypsin Deficiency Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alpha Antitrypsin Deficiency Report Key Strengths

  • 11 Year Forecast
  • 6MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Alpha Antitrypsin Deficiency Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Alpha Antitrypsin Deficiency market
  • Organize sales and marketing efforts by identifying the best opportunities for Alpha Antitrypsin Deficiency market
  • To understand the future market competition in the Alpha Antitrypsin Deficiency market.

Table of Contents

1 Key Insights

2 Executive Summary of Alpha Antitrypsin Deficiency

3 SWOT Analysis for Alpha Antitrypsin Deficiency

4 Patient Share of Alpha Antitrypsin Deficiency at a Glance

  • 4.1 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017
  • 4.2 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030

5 Alpha Antitrypsin Deficiency Market Overview at a Glance

  • 5.1 Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2017
  • 5.2 Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2030

6 Disease Background and Overview

  • 6.1 Introduction
  • 6.2 Symptoms
  • 6.3 Etiology
  • 6.4 Risk Factors
  • 6.5 Genetic Inheritance of AAT Deficiency
  • 6.6 Clinical Manifestations
  • 6.7 Pathophysiology
  • 6.8 Biomarkers
  • 6.9 Diagnosis
  • 6.1 Diagnostic Delay

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM

8 Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency

  • 8.1 Assumptions and Rationale: 6MM
  • 8.2 United States
    • 8.2.1 Prevalence of Symptomatic AATD in the United States
    • 8.2.2 Diagnosed population of AATD in the United States
    • 8.2.3 Genotype of AATD Diagnosed patients in the United States
    • 8.2.4 Comorbidity associated with AATD in the United States
  • 8.3 EU5
    • 8.3.1 Germany
      • 8.3.1.1 Prevalence of Symptomatic AATD in Germany
      • 8.3.1.2 Diagnosed population of AATD in Germany
      • 8.3.1.3 Genotype of AATD Diagnosed patients in Germany
      • 8.3.1.4 Comorbidity associated with AATD in Germany
    • 8.3.2 France
      • 8.3.2.1 Prevalence of Symptomatic AATD in France
      • 8.3.2.2 Diagnosed population of AATD in France
      • 8.3.2.3 Genotype of AATD Diagnosed patients in France
      • 8.3.2.4 Comorbidity associated with AATD in France
    • 8.3.3 Italy
      • 8.3.3.1 Prevalence of Symptomatic AATD in Italy
      • 8.3.3.2 Diagnosed population of AATD in Italy
      • 8.3.3.3 Genotype of AATD Diagnosed patients in Italy
      • 8.3.3.4 Comorbidity associated with AATD in Italy
    • 8.3.4 Spain
      • 8.3.4.1 Prevalence of Symptomatic AATD in Spain
      • 8.3.4.2 Diagnosed population of AATD in Spain
      • 8.3.4.3 Genotype of AATD Diagnosed patients in Spain
      • 8.3.4.4 Comorbidity associated with AATD in Spain
    • 8.3.5 United Kingdom
      • 8.3.5.1 Prevalence of Symptomatic AATD in the United Kingdom
      • 8.3.5.2 Diagnosed population of AATD in the United Kingdom
      • 8.3.5.3 Genotype of AATD Diagnosed patients in the United Kingdom
      • 8.3.5.4 Comorbidity associated with AATD in the United Kingdom

9 Treatment

  • 9.1 Current therapies
    • 9.1.1 Augmentation Therapy
    • 9.1.2 Gene Therapy strategies
    • 9.1.3 Lifestyle Changes
    • 9.1.4 Novel therapeutics

10 Treatment Algorithm

  • 10.1 Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
  • 10.2 Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

11 Unmet Needs

12 Organizations contributing toward Alpha Antitrypsin Deficiency

13 Case Reports

  • 13.1 An unusual case of alpha-1-antitrypsin deficiency: SZ/Z
  • 13.2 The Importance of Early Identification of Alpha-1 Antitrypsin Deficiency
  • 13.3 A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis

14 Marketed Drugs

  • 14.1 Prolastin C: Grifols
    • 14.1.1 Drug Description
    • 14.1.2 Mechanism of Action
    • 14.1.3 Regulatory Milestones
    • 14.1.4 Advantages and Disadvantages
    • 14.1.5 Safety and Efficacy of Prolastin-C
  • 14.2 Glassia: Kamada
    • 14.2.1 Drug Description
    • 14.2.2 Mechanism of Action
    • 14.2.3 Regulatory Milestones
    • 14.2.4 Advantages and Disadvantages
    • 14.2.5 Safety and Efficacy of Glassia
  • 14.3 Aralast: Shire
    • 14.3.1 Drug Description
    • 14.3.2 Mechanism of Action
    • 14.3.3 Regulatory Milestones
    • 14.3.4 Advantages and Disadvantages
    • 14.3.5 Safety and Efficacy of Aralast
  • 14.4 Zemaira: CSL Behring
    • 14.4.1 Drug Description
    • 14.4.2 Mechanism of Action
    • 14.4.3 Regulatory Milestones
    • 14.4.4 Advantages and Disadvantages
    • 14.4.5 Safety and Efficacy of Zemaira
  • 14.5 Alfalastin: LFB Biotechnologies
    • 14.5.1 Description
    • 14.5.2 Regulatory Milestones
    • 14.5.3 Advantages and Disadvantages
    • 14.5.4 Safety and Efficacy
  • 14.6 Trypsone: Grifols
    • 14.6.1 Description
    • 14.6.2 Regulatory Milestones
    • 14.6.3 Advantages and Disadvantages
    • 14.6.4 Efficacy and Safety

15 Emerging Therapies

  • 15.1 Inhaled AAT (Glassia IH): Kamada Ltd
    • 15.1.1 Product Description
    • 15.1.2 Regulatory Milestones
    • 15.1.3 Product Development Activities
    • 15.1.4 Clinical Development
      • 15.1.4.1 Clinical Trials Information
    • 15.1.5 Safety and Efficacy
  • 15.2 ALN-AAT02: Alnylam Pharmaceuticals
    • 15.2.1 Product Description
    • 15.2.2 Product Development Activities
    • 15.2.3 Clinical development
      • 15.2.3.1 Clinical Trials Information
    • 15.2.4 Safety and Efficacy
  • 15.3 ARO-AAT: Arrow Head Pharmaceuticals
    • 15.3.1 Product Description
    • 15.3.2 Product Development Activities
    • 15.3.3 Clinical Development
      • 15.3.3.1 Clinical Trials Information
    • 15.3.4 Safety and Efficacy
  • 15.4 VX-814: Vertex Pharmaceuticals
    • 15.4.1 Product Description
    • 15.4.2 Product Development Activities
    • 15.4.3 Clinical Development
      • 15.4.3.1 Clinical Trials Information
  • 15.5 Alvelestat (MPH-966): Mereo Biopharma
    • 15.5.1 Product Description
    • 15.5.2 Product Development Activities
    • 15.5.3 Clinical Development
      • 15.5.3.1 Clinical Trials Information
  • 15.6 DCR-A1AT: Dicerna Pharmaceuticals
    • 15.6.1 Product Description
    • 15.6.2 Product Development Activities
    • 15.6.3 Clinical Development
      • 15.6.3.1 Clinical Trial Information
    • 15.6.4 Pre-clinical Results

16 Other Promising Candidates

  • 16.1 INBRX-101: Inhibrx
    • 16.1.1 Product Description
    • 16.1.2 Product Development Activities
    • 16.1.3 Clinical development
  • 16.2 Carbamazepine: Novartis Pharmaceuticals
    • 16.2.1 Product Description
    • 16.2.2 Clinical Development
      • 16.2.2.1 Clinical Trials Information
  • 16.3 VX-864: Vertex Pharmaceuticals
    • 16.3.1 Product Description

17 Alpha Antitrypsin Deficiency: 6 Major Market Analysis

  • 17.1 Total Market Size of AATD

18 Alpha Antitrypsin Deficiency: Country-Wise Market Analysis

  • 18.1 United States
    • 18.1.1 Total Market Size of AATD
    • 18.1.2 Market Size of Alpha Antitrypsin Deficiency by Therapies in United States
  • 18.2 EU-5
    • 18.2.1 Germany
      • 18.2.1.1 Total Market Size of AATD in Germany
      • 18.2.1.2 Market Size of Alpha Antitrypsin Deficiency by Therapies in Germany
    • 18.2.2 France
      • 18.2.2.1 Total Market Size of AATD in France
      • 18.2.2.2 Market Size of Alpha Antitrypsin Deficiency by Products in France
    • 18.2.3 Italy
      • 18.2.3.1 Total Market Size of AATD in Italy
      • 18.2.3.2 Market Size of Alpha Antitrypsin Deficiency by Products in Italy
    • 18.2.4 Spain
      • 18.2.4.1 Total Market Size of AATD in Spain
      • 18.2.4.2 Market Size of Alpha Antitrypsin Deficiency by Products in Spain
    • 18.2.5 United Kingdom
      • 18.2.5.1 Total Market Size of AATD in The UK
      • 18.2.5.2 Market Size of Alpha Antitrypsin Deficiency by Products in UK

19 Grifols Initiatives towards Alpha Antitrypsin deficiency

20 US FDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

21 Market Drivers

22 Market Barriers

23 Access and Reimbursement Overview of Alpha Antitrypsin Deficiency

  • 23.1 The Italian Experience
  • 23.2 Augmentation Therapy - slowly finding its way in the UK
  • 23.3 The Changing Future

24 Appendix

  • 24.1 Bibliography
  • 24.2 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

List of Tables

  • Table 1: Summary of Alpha-1 Antitrypsin Deficiency (AATD) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Diagnostic Delay Interval for AATD
  • Table 3: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2017-2030)
  • Table 4: Prevalence of Symptomatic AATD in the United States (2017-2030)
  • Table 5: Diagnosed population of AATD in the United States (2017-2030)
  • Table 6: Genotype of AATD Diagnosed patients in the United States (2017-2030)
  • Table 7: Comorbidity associated with AATD in the United States (2017-2030)
  • Table 8: Prevalence of Symptomatic AATD in Germany (2017-2030)
  • Table 9: Diagnosed population of AATD in Germany (2017-2030)
  • Table 10: Genotype of AATD Diagnosed patients in Germany (2017-2030)
  • Table 11: Comorbidity associated with AATD in Germany (2017-2030)
  • Table 12: Prevalence of Symptomatic AATD in France (2017-2030)
  • Table 13: Diagnosed population of AATD in France (2017-2030)
  • Table 14: Genotype of AATD Diagnosed patients in France (2017-2030)
  • Table 15: Comorbidity associated with AATD in France (2017-2030)
  • Table 16: Prevalence of Symptomatic AATD in Italy (2017-2030)
  • Table 17: Diagnosed population of AATD in Italy (2017-2030)
  • Table 18: Genotype of AATD Diagnosed patients in Italy (2017-2030)
  • Table 19: Comorbidity associated with AATD in Italy (2017-2030)
  • Table 20: Prevalence of Symptomatic AATD in Spain (2017-2030)
  • Table 21: Diagnosed population of AATD in Spain (2017-2030)
  • Table 22: Genotype of AATD Diagnosed patients in Spain (2017-2030)
  • Table 23: Comorbidity associated with AATD in Spain (2017-2030)
  • Table 24: Prevalence of Symptomatic AATD in The United Kingdom (2017-2030)
  • Table 25: Diagnosed population of AATD in The United Kingdom (2017-2030)
  • Table 26: Genotype of AATD Diagnosed patients in The United Kingdom (2017-2030)
  • Table 27: Comorbidity associated with AATD in The United Kingdom (2017-2030)
  • Table 28: Organizations contributing toward Alpha-Antitrypsin Deficiency
  • Table 29: Inhaled AAT, Clinical Trial Description, 2020
  • Table 30: ALN-AAT02, Clinical Trial Description, 2020
  • Table 31: ARO-AAT, Clinical Trial Description, 2020
  • Table 32: VX-814, Clinical Trial Description, 2020
  • Table 33: Alvelestat, Clinical Trial Description, 2020
  • Table 34: DCR-A1AT, Clinical Trial Description, 2020
  • Table 35: INBRX-101, Clinical Trial Description, 2020
  • Table 36: Carbamazepine, Clinical Trial Description, 2020
  • Table 37: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 38: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 39: US Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)
  • Table 40: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 41: Germany Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)
  • Table 42: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 43: France Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
  • Table 44: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017 -2030)
  • Table 45: Italy Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
  • Table 46: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017 -2030)
  • Table 47: Spain Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
  • Table 48: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 49: UK Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)

List of Figures

FIGURE 1: SWOT ANALYSIS

FIGURE 2: HISTORICAL OVERVIEW OF AATD DEVELOPMENT

FIGURE 3: SYMPTOMS ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 4: RISK FACTORS FOR AATD

FIGURE 5: INHERITANCE OF AATD

FIGURE 6: INHERITANCE PATTERN OF AATD

FIGURE 7: ALPHA-1 ANTITRYPSIN BINDS AND INACTIVATES NEUTROPHIL ELASTASE.

FIGURE 8: PATHOGENESIS OF ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 9: DIAGNOSTIC ALGORITHM OF ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 10: ATS/ERS DIAGNOSTIC RECOMMENDATIONS FOR ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 11: ATS/ERS RECOMMENDATIONS (TO BE DISCUSSED) FOR ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 12: ATS/ERS DIAGNOSTIC RECOMMENDATIONS (NOT RECOMMENDED) FOR ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 13: DIAGNOSTIC AND MONITORING METHODS FOR ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 14: TOTAL PREVALENT POPULATION OF ALPHA-1-ANTITRYPSIN DEFICIENCY IN 6 MM (2017-2030)

FIGURE 15: PREVALENCE OF SYMPTOMATIC AATD IN THE UNITED STATES (2017-2030)

FIGURE 16: DIAGNOSED POPULATION OF AATD IN THE UNITED STATES (2017-2030)

FIGURE 17: GENOTYPE OF AATD DIAGNOSED PATIENTS IN THE UNITED STATES (2017-2030)

FIGURE 18: COMORBIDITY ASSOCIATED WITH AATD IN THE UNITED STATES (2017-2030)

FIGURE 19: PREVALENCE OF SYMPTOMATIC AATD IN GERMANY (2017-2030)

FIGURE 20: DIAGNOSED POPULATION OF AATD IN GERMANY (2017-2030)

FIGURE 21: GENOTYPE OF AATD DIAGNOSED PATIENTS IN GERMANY (2017-2030)

FIGURE 22: COMORBIDITY ASSOCIATED WITH AATD IN GERMANY (2017-2030)

FIGURE 23: PREVALENCE OF SYMPTOMATIC AATD IN FRANCE (2017-2030)

FIGURE 24: DIAGNOSED POPULATION OF AATD IN FRANCE (2017-2030)

FIGURE 25: GENOTYPE OF AATD DIAGNOSED PATIENTS IN FRANCE (2017-2030)

FIGURE 26: COMORBIDITY ASSOCIATED WITH AATD IN FRANCE (2017-2030)

FIGURE 27: PREVALENCE OF SYMPTOMATIC AATD IN ITALY (2017-2030)

FIGURE 28: DIAGNOSED POPULATION OF AATD IN ITALY (2017-2030)

FIGURE 29: GENOTYPE OF AATD DIAGNOSED PATIENTS IN ITALY (2017-2030)

FIGURE 30: COMORBIDITY ASSOCIATED WITH AATD IN ITALY (2017-2030)

FIGURE 31: PREVALENCE OF SYMPTOMATIC AATD IN SPAIN (2017-2030)

FIGURE 32: DIAGNOSED POPULATION OF AATD IN SPAIN (2017-2030)

FIGURE 33: GENOTYPE OF AATD DIAGNOSED PATIENTS IN SPAIN (2017-2030)

FIGURE 34: COMORBIDITY ASSOCIATED WITH AATD IN SPAIN (2017-2030)

FIGURE 35: PREVALENCE OF SYMPTOMATIC AATD IN THE UNITED KINGDOM (2017-2030)

FIGURE 36: DIAGNOSED POPULATION OF AATD IN THE UNITED KINGDOM (2017-2030)

FIGURE 37: GENOTYPE OF AATD DIAGNOSED PATIENTS IN THE UNITED KINGDOM (2017-2030)

FIGURE 38: COMORBIDITY ASSOCIATED WITH AATD IN THE UNITED KINGDOM (2017-2030)

FIGURE 39: TREATMENT RECOMMENDATIONS FOR AATD

FIGURE 40: AVAILABLE THERAPEUTICS OF ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 41: STRATEGIES FOR DELIVERY OF ENGINEERED NUCLEASES: A) EX-VIVO ; B) IN VIVO

FIGURE 42:GENOME EDITING WITH ENGINEERED NUCLEASES

FIGURE 43: TREATMENT ALGORITHM OF ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 44: ALGORITHM FOR MANAGEMENT OF ALPHA ANTITRYPSIN DEFICIENCY WITH LUNG DISEASE

FIGURE 45: ALGORITHM FOR MANAGEMENT OF ALPHA ANTITRYPSIN DEFICIENCY WITH LUNG DISEASE

FIGURE 46: CURRENT UNMET NEEDS

FIGURE 47: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017-2030)

FIGURE 48: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017-2030)

FIGURE 49: US MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2030)

FIGURE 50: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017-2030)

FIGURE 51: GERMANY MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017-2030)

FIGURE 52: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017-2030)

FIGURE 53: FRANCE MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017-2030)

FIGURE 54: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2030)

FIGURE 55: ITALY MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017-2030)

FIGURE 56: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2030)